Literature DB >> 34595771

Long-Term Cognitive Outcome in Anti-N-Methyl-D-Aspartate Receptor Encephalitis.

Josephine Heine1,2, Ute A Kopp1, Johanna Klag1, Christoph J Ploner1, Harald Prüss1,3, Carsten Finke1,4,5.   

Abstract

OBJECTIVE: Cognitive dysfunction is a core symptom of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, but detailed studies on prevalence, characteristics of cognitive deficits, and the potential for recovery are missing. Here, we performed a prospective longitudinal study to assess cognitive long-term outcome and identify clinical predictors.
METHODS: Standardized comprehensive neuropsychological assessments were performed in 43 patients with NMDAR encephalitis 2.3 years and 4.9 years (median) after disease onset. Cognitive assessments covered executive function, working memory, verbal/visual episodic memory, attention, subjective complaints, and depression and anxiety levels. Cognitive performance of patients was compared to that of 30 healthy participants matched for age, sex, and education.
RESULTS: All patients had persistent cognitive deficits 2.3 years after onset, with moderate or severe impairment in >80% of patients. Core deficits included memory and executive function. After 4.9 years, significant improvement of cognitive function was observed, but moderate to severe deficits persisted in two thirds of patients, despite favorable functional neurological outcomes (median modified Rankin Scale = 1). Delayed treatment, higher disease severity, and longer duration of the acute phase were predictors for impaired cognitive outcome. The recovery process was time dependent, with greater gains earlier after the acute phase, although improvements were possible for several years after disease onset.
INTERPRETATION: Cognitive deficits are the main contributor to long-term morbidity in NMDAR encephalitis and persist beyond functional neurological recovery. Nonetheless, cognitive improvement is possible for several years after the acute phase and should be supported by continued cognitive rehabilitation. Cognition should be included as an outcome measure in future clinical studies. ANN NEUROL 2021;90:949-961.
© 2021 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Entities:  

Mesh:

Year:  2021        PMID: 34595771     DOI: 10.1002/ana.26241

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  7 in total

1.  Younger Age at Onset Is Associated With Worse Long-term Behavioral Outcomes in Anti-NMDA Receptor Encephalitis.

Authors:  Anusha Yeshokumar; Eliza Gordon-Lipkin; Ana Arenivas; Mark Rosenfeld; Kristina Patterson; Raia Blum; Brenda Banwell; Arun Venkatesan; Eric Lancaster; Jessica Panzer; John Probasco
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-07-06

Review 2.  Life after autoantibody-mediated encephalitis: optimizing follow-up and management in recovering patients.

Authors:  Pierpaolo Turcano; Gregory S Day
Journal:  Curr Opin Neurol       Date:  2022-06-01       Impact factor: 6.283

3.  CSF-Neurofilament Light Chain Levels in NMDAR and LGI1 Encephalitis: A National Cohort Study.

Authors:  Mette Scheller Nissen; Matias Ryding; Anna Christine Nilsson; Jonna Skov Madsen; Dorte Aalund Olsen; Ulrich Halekoh; Magnus Lydolph; Zsolt Illes; Morten Blaabjerg
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

4.  State-dependent signatures of anti-N-methyl-d-aspartate receptor encephalitis.

Authors:  Nina von Schwanenflug; Stephan Krohn; Josephine Heine; Friedemann Paul; Harald Prüss; Carsten Finke
Journal:  Brain Commun       Date:  2022-02-01

5.  Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis.

Authors:  Adam Al-Diwani; Jakob Theorell; Valentina Damato; Joshua Bull; Nicholas McGlashan; Edward Green; Anne Kathrin Kienzler; Ruby Harrison; Tasneem Hassanali; Leticia Campo; Molly Browne; Alistair Easton; Hooman Soleymani Majd; Keiko Tenaka; Raffaele Iorio; Russell C Dale; Paul Harrison; John Geddes; Digby Quested; David Sharp; Soon Tae Lee; David W Nauen; Mateusz Makuch; Belinda Lennox; Darren Fowler; Fintan Sheerin; Patrick Waters; M Isabel Leite; Adam E Handel; Sarosh R Irani
Journal:  Brain       Date:  2022-08-27       Impact factor: 15.255

6.  Long-term-video monitoring EEG and 18F-FDG-PET are useful tools to detect residual disease activity in anti-LGI1-Abs encephalitis: A case report.

Authors:  Sara Cornacchini; Antonio Farina; Margherita Contento; Valentina Berti; Martina Biggi; Alessandro Barilaro; Luca Massacesi; Valentina Damato; Eleonora Rosati
Journal:  Front Neurol       Date:  2022-08-16       Impact factor: 4.086

Review 7.  Deciphering the contributions of neuroinflammation to neurodegeneration: lessons from antibody-mediated encephalitis and coronavirus disease 2019.

Authors:  Dror Shir; Gregory S Day
Journal:  Curr Opin Neurol       Date:  2022-04-01       Impact factor: 5.710

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.